Latest Period
Q4 2025
Security Snapshot
Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) Institutional Ownership
CUSIP: M47238148
13F Institutional Holders and Ownership History from Q3 2024 to Q4 2025
Institutions Reporting
16
Shares (Excl. Options)
221,660
Price
$0.75
- Type / Class
- Equity / Ordinary Shares, NIS 1.80 par value per share
- Symbol
- GLMD on Nasdaq
- Shares outstanding
- 5,591,387
- Price per share
- $0.84
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 221,660
- Total reported value
- $166,356
- % of total 13F portfolios
- 0%
- Share change
- +147,936
- Value change
- +$111,011
- Number of holders
- 16
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- GLMD - Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share is tracked under CUSIP M47238148.
- 16 institutions reported positions in Q4 2025.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 13 to 16 between Q3 2025 and Q4 2025.
- Reported value moved from $102,011 to $166,356.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Official SEC Source
Backed by Form 13F
Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.
See Original FilingInvestment Quick Answers
What is CUSIP M47238148?
CUSIP M47238148 identifies GLMD - Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue Investment Research
- Latest 13F filings for new institutional portfolio disclosures.
- Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
- Latest 10-Q/10-K reports to cross-check issuer fundamentals.
- Recent insider transactions for management buying/selling context.
- SEC investors directory and top value investors for manager-level discovery.
- All institutional ownership pages to compare adjacent CUSIP pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP M47238148:
Significant Owners of Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| CVI Investments, Inc. | 3.1% | -57% | $346,666 | 173,333 | 0% | CVI Investments, Inc. | 30 Sep 2025 | |
| Baharaff Allen | 2.6% | $60,455 | 44,128 | Allen Baharaff | 31 Dec 2024 |
As of 31 Dec 2025, 16 institutional investors reported holding 221,660 shares of Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD). This represents 4% of the company’s total 5,591,387 outstanding shares.
Institutional Holders of Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 221,660 | $166,356 | +$111,011 | $0.75 | 16 |
| 2025 Q3 | 72,824 | $102,011 | -$18,462 | $1.38 | 13 |
| 2025 Q2 | 75,987 | $140,174 | +$46,243 | $1.86 | 14 |
| 2025 Q1 | 55,876 | $80,439 | +$15,875 | $1.44 | 12 |
| 2024 Q4 | 44,767 | $142,806 | +$124,943 | $3.19 | 11 |
| 2024 Q3 | 5,585 | $38,313 | +$38,306 | $6.86 | 9 |